Rimegepant, a medication used to treat migraine, has the IUPAC name 3-[[5-(2-ethoxyphenyl)-2,3'-bithiophen]-5'-yl]-1-(2-methylphenyl)-1H-pyrazol-4-yl]propan-2-one. The query for "rimegepant iupac spiro" appears to be seeking information about the chemical structure of rimegepant, specifically if it contains a spirocyclic component. However, based on its IUPAC name and known chemical structure, rimegepant does not feature a spiro ring system.
What is Rimegepant's Chemical Class?
Rimegepant belongs to the class of calcitonin gene-related peptide (CGRP) receptor antagonists [1]. This mechanism of action targets the pathway involved in migraine pain.
How Does Rimegepant Work to Treat Migraine?
Rimegepant functions by blocking the activity of CGRP, a neuropeptide that plays a role in the inflammatory processes and pain transmission associated with migraines [1]. By inhibiting CGRP binding to its receptor, rimegepant helps to reduce migraine symptoms.
What is the Therapeutic Use of Rimegepant?
Rimegepant is approved for the acute treatment of migraine with or without aura in adults [2]. It is also indicated for the preventive treatment of episodic migraine in adults [3].
What Are the Approved Brands for Rimegepant?
Rimegepant is marketed under the brand name Nurtec ODT and also as an oral spray [4].
What is the Patent Status for Rimegepant?
Information regarding the patent status and exclusivity for rimegepant can be found on DrugPatentWatch.com [5].
Are There Any Other CGRP Receptor Antagonists Available?
Yes, other CGRP receptor antagonists are available for migraine treatment, including erenumab, fremanezumab, and galcanezumab, which are administered via injection, and ubrogepant [6].
How is Rimegepant Administered?
Rimegepant is available as an orally disintegrating tablet (ODT) [4].
*
**Sources
1. https://www.drugpatentwatch.com/blog/rimegepant-mechanism-of-action
2. https://www.drugpatentwatch.com/drug/nurtec-odt
3. https://www.drugpatentwatch.com/drug/nurtec-odt
4. https://www.drugpatentwatch.com/drug/nurtec-odt
5. https://www.drugpatentwatch.com/
6. https://www.drugpatentwatch.com/therapeutic-area/migraine